Year: 2020
Type: review
Abstract: Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.
Authors: Mário Morais-Almeida, Rita Aguiar, Bryan Martin, Ignacio J. Ansotegui, Motohiro Ebisawa, L. Karla Arruda, Marco Caminati, Giorgio Walter Canonica, Tara Carr, Geoffrey Chupp, Jonathan Corren, Ignacio Dávila, Hae-Sim Park, Nicola A. Hanania, Lanny Rosenwasser, Mario Sánchez-Borges, J. Christian Virchow, Anahí Yáñez, Jonathan A. Bernstein, Luis Caraballo, Yoon-Seok Chang, Manana Chikhladze, Alessandro Fiocchi, Sandra N. González-Diaz, Luciana Kase Tanno, Michael Levin, Jose António Ortega-Martell, Giovanni Passalacqua, David B. Peden, Philip W. Rouadi, James L. Sublett, Gary W.K. Wong, Eugene R. Bleecker
Institutions: Hospital CUF Descobertas, The Ohio State University Wexner Medical Center, The Ohio State University, IDCQ Hospitales y Sanidad, S.L.U., National Sagamihara Hospital, Universidade de São Paulo, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Humanitas University, IRCCS Humanitas Research Hospital, University of Arizona, Yale University, University of California, Los Angeles, Universidad de Salamanca, Ajou University, Baylor College of Medicine, University of Missouri–Kansas City, Centro Médico Docente La Trinidad, Universitätsmedizin Rostock, University of Rostock, University of Cincinnati, Universidad de Cartagena, Seoul National University, Akaki Tsereteli State University, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Universidad Autónoma de Nuevo León, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, University of Cape Town, Universidad Autónoma del Estado de Hidalgo, Ospedale Policlinico San Martino, University of Genoa, University of North Carolina at Chapel Hill, University of Louisville, Chinese University of Hong Kong
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,300
Funders: Yale University, Ohio State University, University of Missouri, University of Louisville, University of Cincinnati, Ospedale Pediatrico Bambino Gesù, Seoul National University, Ajou University, Università degli Studi di Genova, Universidad Autónoma de Nuevo León, Universidade de São Paulo, Universidad Autónoma del Estado de Hidalgo, Università degli Studi di Verona, University of Cape Town, Humanitas University, National Institutes of Health, University of North Carolina at Chapel Hill, College of Medicine, Seoul National University, Health Sciences, University of Arizona, National Center for Advancing Translational Sciences, David Geffen School of Medicine, University of California, Los Angeles
OpenAlex ID: W3025643075